Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3010% above fair value
$957.76+5.36 (+0.56%)
Close on Nov 17, 2026Market cap $99.08BP/E 21.2Yield –
Regeneron Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Regeneron Pharmaceuticals's pe ratio was 23.7× on Nov 11, 2026, against 18.7× a year earlier. Over the last 5 years it ranged from 8.2× to 31.9×, with a median of 18.6×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 23.7× | +5.2 |
| 2025 | Dec 31, 2025 | 18.5× | +0.9 |
| 2024 | Dec 31, 2024 | 17.6× | −7.4 |
| 2023 | Dec 29, 2023 | 25.1× | +9.8 |
| 2022 | Dec 30, 2022 | 15.2× | +5.1 |
| 2021 | Dec 31, 2021 | 10.1× | −7.6 |
| 2020 | Dec 31, 2020 | 17.7× | −2.4 |
| 2019 | Dec 31, 2019 | 20.1× | −3.8 |
| 2018 | Dec 31, 2018 | 23.9× | −10.3 |
| 2017 | Dec 29, 2017 | 34.1× | −19.1 |
| 2016 | Dec 30, 2016 | 53.3× | −56.4 |
| 2015 | Dec 31, 2015 | 109.7× | −24.8 |
| 2014 | Dec 31, 2014 | 134.5× | +95.3 |
| 2013 | Dec 31, 2013 | 39.2× | −48.5 |
| 2012 | Dec 31, 2012 | 87.7× | – |
See a number that looks wrong?